NO20052277L - Behandling av syndrom X med substituerte tetraliner og indaner - Google Patents

Behandling av syndrom X med substituerte tetraliner og indaner

Info

Publication number
NO20052277L
NO20052277L NO20052277A NO20052277A NO20052277L NO 20052277 L NO20052277 L NO 20052277L NO 20052277 A NO20052277 A NO 20052277A NO 20052277 A NO20052277 A NO 20052277A NO 20052277 L NO20052277 L NO 20052277L
Authority
NO
Norway
Prior art keywords
indanes
syndrome
treatment
substituted tetralines
tetralines
Prior art date
Application number
NO20052277A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052277D0 (no
Inventor
Keith Demarest
Jay M Matthews
Xiaoli Chen
Jung Lee
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20052277D0 publication Critical patent/NO20052277D0/no
Publication of NO20052277L publication Critical patent/NO20052277L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052277A 2002-10-21 2005-05-10 Behandling av syndrom X med substituerte tetraliner og indaner NO20052277L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41992702P 2002-10-21 2002-10-21
US49575803P 2003-08-15 2003-08-15
PCT/US2003/033088 WO2004037777A1 (en) 2002-10-21 2003-10-17 Treating syndrome x with substituted tetralins and indanes

Publications (2)

Publication Number Publication Date
NO20052277D0 NO20052277D0 (no) 2005-05-10
NO20052277L true NO20052277L (no) 2005-06-29

Family

ID=32179770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052277A NO20052277L (no) 2002-10-21 2005-05-10 Behandling av syndrom X med substituerte tetraliner og indaner

Country Status (17)

Country Link
US (2) US20040171680A1 (pl)
EP (1) EP1556344A1 (pl)
JP (1) JP2006503915A (pl)
KR (1) KR20050067419A (pl)
AU (1) AU2003279981A1 (pl)
BR (1) BR0315566A (pl)
CA (1) CA2503405A1 (pl)
CO (1) CO5690541A2 (pl)
EA (1) EA200500517A1 (pl)
HR (1) HRP20050337A2 (pl)
MX (1) MXPA05004296A (pl)
NO (1) NO20052277L (pl)
NZ (1) NZ539432A (pl)
PL (1) PL376470A1 (pl)
RS (1) RS20050319A (pl)
TW (1) TW200412935A (pl)
WO (1) WO2004037777A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009553B1 (ru) * 2002-10-21 2008-02-28 Янссен Фармацевтика Н.В. Замещённые тетралины и инданы
DK1554240T3 (da) * 2002-10-21 2009-08-17 Janssen Pharmaceutica Nv Substituerede tetraliner og indaner og deres anvendelse
EP1667958A2 (en) 2003-10-01 2006-06-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
AR048931A1 (es) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
US7550467B2 (en) * 2004-10-12 2009-06-23 Schering Corporation Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
US20060263450A1 (en) * 2005-05-17 2006-11-23 Julius Oben Method and composition for reducing body weight and improving control of body lipids
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US20100098793A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, ldl cholesterol, blood glucose, c-reactive protein, and leptin levels and increasing adiponectin levels
US20100098792A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Methods and compositions using irvingia gabonensis to reduce weight, control obesity, effect adipogenesis, lower ppar-gamma, leptin, g3pdh and triglycerides levels and increase adiponectin levels
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy
WO2016092547A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Alcoholic beverage substitutes
WO2016092546A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
JP2003523336A (ja) * 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
BR0114437A (pt) * 2000-10-05 2003-07-01 Bayer Ag Derivados de acido propiÈnico
AU2002222549A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002046146A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
EA009553B1 (ru) * 2002-10-21 2008-02-28 Янссен Фармацевтика Н.В. Замещённые тетралины и инданы
DK1554240T3 (da) * 2002-10-21 2009-08-17 Janssen Pharmaceutica Nv Substituerede tetraliner og indaner og deres anvendelse

Also Published As

Publication number Publication date
WO2004037777A1 (en) 2004-05-06
HRP20050337A2 (en) 2005-12-31
EP1556344A1 (en) 2005-07-27
KR20050067419A (ko) 2005-07-01
NZ539432A (en) 2008-04-30
PL376470A1 (pl) 2005-12-27
BR0315566A (pt) 2005-08-23
CA2503405A1 (en) 2004-05-06
AU2003279981A1 (en) 2004-05-13
RS20050319A (sr) 2007-09-21
MXPA05004296A (es) 2005-11-23
NO20052277D0 (no) 2005-05-10
EA200500517A1 (ru) 2005-10-27
JP2006503915A (ja) 2006-02-02
CO5690541A2 (es) 2006-10-31
TW200412935A (en) 2004-08-01
US20040171680A1 (en) 2004-09-02
US20040162352A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
DK1599468T3 (da) 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
GEP20074197B (en) 5ht2c receptor modulators
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
NO20071222L (no) Benzamidforbindelser.
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
SG165315A1 (en) Alpha2c adrenoreceptor agonists
NO20050294L (no) Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser
NO20062511L (no) Fenoksy-eddiksyrederivater anvendelige som peroksisomproliferator-aktiverende reseptor (PPAR) dualagonister
NO20071919L (no) 4-((fenoksyalkyl)tio)-fenoksyeddiksyre og analoger
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
NO20082505L (no) Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer
NO20071920L (no) 4-((fenoksyalkyl)tio)-fenoksyeddiksyre og analoger
EA200500517A1 (ru) Лечение синдрома х замещёнными тетралинами и инданами
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
DE60329326D1 (de) Tace inhibitoren
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DK1554240T3 (da) Substituerede tetraliner og indaner og deres anvendelse
NO20052199L (no) Substituerte tetraliner og indaner